{"nctId":"NCT00271817","briefTitle":"To Evaluate Ezetimibe/Simvastatin and Niacin (Extended Release Tablet) in Patients With Type IIa or Type IIb Hyperlipidemia (0653A-091)(COMPLETED)","startDateStruct":{"date":"2005-12"},"conditions":["Hypercholesterolemia"],"count":1220,"armGroups":[{"label":"Part 1 - Arm 1","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Comparator: ezetimibe/simvastatin + niacin (ER)"]},{"label":"Part 1 -Arm 2","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Comparator: ezetimibe (+) simvastatin","Drug: Comparator: Placebo to Niacin (ER)"]},{"label":"Part 1 - Arm 3","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Comparator: Placebo to ezetimibe/simvastatin","Drug: Comparator: niacin (ER) tablet"]},{"label":"Part 2 - Arm 1","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Comparator: ezetimibe/simvastatin and niacin (ER)"]},{"label":"Part 2 - Arm 2","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Comparator: ezetimibe and simvastatin","Drug: Comparator: Placebo to niacin (ER)"]}],"interventions":[{"name":"Comparator: ezetimibe/simvastatin + niacin (ER)","otherNames":[]},{"name":"Comparator: Placebo to ezetimibe/simvastatin","otherNames":[]},{"name":"Comparator: niacin (ER) tablet","otherNames":[]},{"name":"Comparator: ezetimibe (+) simvastatin","otherNames":[]},{"name":"Comparator: Placebo to Niacin (ER)","otherNames":[]},{"name":"Comparator: ezetimibe/simvastatin and niacin (ER)","otherNames":[]},{"name":"Comparator: ezetimibe and simvastatin","otherNames":[]},{"name":"Comparator: Placebo to niacin (ER)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patient with LDL-C of 130 through 190 mg/dL and Triglycerides less than or equal to 500 mg/dL\n* Patient willing to be on a low-cholesterol diet\n\nExclusion Criteria:\n\n* Pregnant or lactating women or intending to become pregnant\n* Patient with sensitivity or intolerance to ezetimibe, simvastatin, or ezetimibe/simvastatin combination tablet\n* Patient with sensitivity or intolerance ro niacin, any component or niacin extended release or aspirin\n* Patient for whom discontinuation of existing lipid-lowering therapy treatment poses an unacceptable risk","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"79 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percent Change From Baseline in Low-Density Lipoprotein-Cholesterol (LDL-C)","description":"Ezetimibe/simvastatin co-administered with niacin extended release compared to niacin extended release monotherapy on the percent change, from baseline in LDL-C after 24 weeks - 24 Week Measure Minus Baseline","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-20.1","spread":"1.3"},{"groupId":"OG001","value":"-58.5","spread":"0.8"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Non-High-Density Lipoprotein-Cholesterol (Non-HDL-C)","description":"Ezetimibe/simvastatin co-administered with niacin extended release compared to niacin extended release monotherapy on the percent change from baseline in non-HDL-C after 24 weeks - 24 week measure minus baseline","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-22.0","spread":"1.3"},{"groupId":"OG001","value":"-55.6","spread":"0.8"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in High-Density Lipoprotein-Cholesterol (HDL-C)","description":"Ezetimibe/simvastatin co-administered with niacin extended release compared to ezetimibe/simvastatin monotherapy on the percent change from baseline in HDL-C after 24 weeks - 24 week measure minus baseline","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.1","spread":"1.3"},{"groupId":"OG001","value":"30.2","spread":"1.0"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Triglycerides (TG)","description":"Ezetimibe/simvastatin co-administered with niacin extended release compared to ezetimibe/simvastatin monotherapy on the percent change from baseline in Triglycerides after 24 weeks - 24 week measure minus baseline","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23.7","spread":"29.7"},{"groupId":"OG001","value":"-42.5","spread":"27.5"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in High-Density Lipoprotein-Cholesterol (HDL-C)","description":"Ezetimibe/simvastatin co-administered with niacin extended release compared to ezetimibe/simvastatin monotherapy on the percent change from baseline in HDL-C after 64 weeks - 64 week measure minus baseline","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.0","spread":"1.4"},{"groupId":"OG001","value":"30.5","spread":"1.1"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Triglycerides (TG)","description":"Ezetimibe/simvastatin co-administered with niacin extended release compared to ezetimibe/simvastatin monotherapy on the percent change from baseline in Triglycerides after 64 weeks - 64 week measure minus baseline","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-26.8","spread":"32.7"},{"groupId":"OG001","value":"-44.5","spread":"26.9"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Non-High-Density Lipoprotein-Cholesterol (Non-HDL-C)","description":"Ezetimibe/simvastatin co-administered with niacin extended release compared to ezetimibe/simvastatin monotherapy on the percent change from baseline in non-HDL-C after 64 weeks - 64 week measure minus baseline","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-45.1","spread":"1.3"},{"groupId":"OG001","value":"-52.4","spread":"0.9"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Low-Density Lipoprotein-Cholesterol (LDL-C)","description":"Ezetimibe/simvastatin co-administered with niacin extended release compared to ezetimibe/simvastatin monotherapy on the percent change from baseline in LDL-C after 64 weeks - 64 week measure minus baseline","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-49.3","spread":"1.3"},{"groupId":"OG001","value":"-54.0","spread":"1.0"}]}]}]},{"type":"PRIMARY","title":"Percent Change From Baseline in Low-Density Lipoprotein-Cholesterol (LDL-C)","description":"Ezetimibe/simvastatin co-administered with niacin extended release compared to ezetimibe/simvastatin monotherapy on the percent change from baseline in LDL-C after 24 weeks - 24 week measure minus baseline","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-53.5","spread":"1.2"},{"groupId":"OG001","value":"-58.5","spread":"0.8"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Non-High-Density Lipoprotein-Cholesterol (Non-HDL-C)","description":"Ezetimibe/simvastatin co-administered with niacin extended release compared to ezetimibe/simvastatin monotherapy on the percent change from baseline in non-HDL-C after 24 weeks - 24 week measure minus baseline","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-47.9","spread":"1.1"},{"groupId":"OG001","value":"-55.6","spread":"0.8"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":8},"commonTop":["Flushing","Pruritus","Upper Respiratory Tract Infection","Diarrhoea","Rash"]}}}